Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
Date:5/6/2008

e rapid onset of action."

"Reaching the patient enrollment target in our Phase III clinical trial of Omigard for the prevention of catheter-related infections is a major milestone in our clinical development program for this product candidate," stated James Breitmeyer, M.D., Ph.D., Executive Vice President, Development and Chief Medical Officer of Cadence. "If approved, we believe that Omigard will address a rapidly growing need for more effective ways to lower hospital acquired infection rates, including the dangerous and costly complications from infections related to intravascular catheters."

Cadence's second clinical trial of Acetavance for the treatment of fever in adults, designated Study 303, was a Phase III, randomized, double-blind, double-dummy, single-dose study of intravenous acetaminophen (1 gram) compared to oral acetaminophen (1 gram) for the treatment of fever in 81 adult volunteers with experimentally-induced fever. In this study, a statistically significant difference in favor of Acetavance was observed compared to oral acetaminophen for the primary efficacy endpoint of WSTD2 (the weighted sum of temperature differences over two hours) (p< 0.01). The mean temperature scores for patients in the Acetavance-treated group were significantly lower as early as 15 minutes after the study drug was administered. The peak temperature observed in the Acetavance group of patients was also significantly lower. Acetavance was very well tolerated, including no treatment-emergent serious adverse events or treatment-emergent hepatic adverse events.

Cadence's confirmatory Phase III clinical trial of Omigard (omiganan pentahydrochloride 1% gel), known as the Central Line Infection Reduction Study, or CLIRS, is a randomized, evaluator-blinded study in hospitalized patients whose medical condition requires a short-term central venous catheter. The primary objective of CLIRS is to evaluate the efficacy and safety of Omigard compared to 10% povidone-
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
2. Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates
3. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
4. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
5. Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 3454
6. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
7. ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
8. Cequent Pharmaceuticals Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008
9. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
10. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
11. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Calif. , Oct. 22, 2014  AcelRx ... announced that results from the  IAP310 study have ... Medicine (RAPM), a peer-reviewed journal with broad, ... 3 trial evaluating the safety and efficacy of ... tablet system (SSTS), for the treatment of post-operative ...
(Date:10/20/2014)... , 20 de octubre de 2014 /PRNewswire/ ... el campo de la pulmonología intervencional, anunció hoy ... RENEW, casi 3 meses antes de lo programado. El ... exención de dispositivo de investigación (IDE) aprobada por ... el sistema de espiral de reducción de volumen ...
(Date:10/20/2014)... BioNano Genomics announced today achievement of a major milestone ... at 30X depth, sufficient for a genome map, in 24 ... and demonstrated for the IrysChip TM V2, the high-throughput ... will be rolled out to BioNano,s collaborators and customers over ... at the American Society for Human Genetics (ASHG) 2014 ...
Breaking Medicine Technology:AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3
... Inhibitor-, SOUTH SAN FRANCISCO, Calif., Jan. 7 ... has initiated a phase 1/2 trial,of XL184 in patients ... disease while on a regimen containing erlotinib., XL184 ... RET and,VEGFR receptor tyrosine kinases. In the initial phase ...
... scientists today,report that the genetic variant on chromosome ... of heart attack is also associated with up ... (AAA) and intracranial,aneurysm (IA). This is the first ... condition. The paper, entitled ,The same sequence,variant on ...
Cached Medicine Technology:Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer 2Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer 3Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer 4Not Only Lipids and Inflammation: Insight Into a New Cause of Heart Attack and Other Vascular Disease 2Not Only Lipids and Inflammation: Insight Into a New Cause of Heart Attack and Other Vascular Disease 3
(Date:10/22/2014)... Mission Viejo, CA (PRWEB) October 22, 2014 ... that Jay Cormier, Sr. Vice President of Sales, will ... at the upcoming Meetings Technology Expo on October 28, ... will also be hosting a booth as well as ... on how Lintelus Meeting can create a more engaging ...
(Date:10/22/2014)... By Maureen Salamon ... -- Black women undergoing in vitro fertilization (IVF) are only ... using the popular assisted reproduction technique, new research indicates, and ... In the study, about 31 percent of white patients ... black patients. Analyzing more than 4,000 IVF cycles over ...
(Date:10/22/2014)... Measures taken by Firestone officials at the company,s ... the spread of the disease there and could prove ... Co. provides health services to about 80,000 employees, retirees, ... Between Aug. 1 and Sept. 23, there were ... people. That incidence rate of 0.09 percent was much ...
(Date:10/20/2014)... 2014 With a mere 19 days ... made a brief fundraising stop at the  Law ... Fresh from a debate last night with his opponent ... for the first seven minutes because Crist had an ... the incident in one word: "weird." , Before touching ...
(Date:10/20/2014)... Women’s health specialist, Dr. Amber Murphy, MD, Ob/Gyn ... Inc., A Division of MaternOhio Clinical Associates, Inc., who ... patients annually. Dr. Murphy will provide a full range ... women’s life. She is accepting new patients at two ... , Dr. Murphy offers a wide variety of services ...
Breaking Medicine News(10 mins):Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3
... (HealthDay News) -- Feelings of shame, social isolation and rejection ... finds. The findings may help explain why depression is ... other kinds of cancer, according to the researchers at the ... association with tobacco use, lung cancer is commonly viewed as ...
... a key mechanism that causes breast cancer to spread. The ... journal Molecular Cell , enhances our knowledge about the ... for a lethal form of invasive breast cancer that is ... ErbB2 has been linked with aggressive forms of breast cancer ...
... irritable bowel syndrome (IBS) have a significantly greater prevalence ... as well as physical, emotional and sexual abuse, according ... Hepatology, the official journal of the American Gastroenterological ... associated with the development of irritable bowel syndrome, particularly ...
... most common kidney cancer subtype, face a low risk of ... key findings of a multi-centre study of nearly 600 patients ... BJUI . "Because papillary renal cell ... patients, the small number of patients enrolled in individual studies ...
... strategy includes a plan to ensure that General Practitioners (GPs) ... 23 March 2012, downloadable from http://www.homeoffice.gov.uk/publications/ ). There is ... The big question is, what should GPs say to their ... scientific journal Addiction analysed the advice given by ...
... PHILADELPHIA Patients with end-stage liver disease complicated by ... carcinoma (HCC) are less likely to die or ... a new liver than those with other complications of ... Perelman School of Medicine at the University of Pennsylvania. ...
Cached Medicine News:Health News:Stigma, Shame Can Worsen Depression in Lung Cancer Patients 2Health News:Researchers identify mechanism that makes breast cancer invasive 2Health News:Childhood traumatic experiences associated with adult IBS symptoms 2Health News:Kidney cancer subtype study finds low recurrence and cancer death rates 2Health News:Penn researchers call for a re-examination of transplant waitlist prioritization 2Health News:Penn researchers call for a re-examination of transplant waitlist prioritization 3
... Wrist Fixator is now available in a ... necessary instrumentation. The surgical technique is printed ... reference. , ,This fixator allows the surgeon ... making multipaner adjustments in the frame via ...
... The WristJack External Fixation System for ... palmar tilt, radial inclination, length and rotation. ... to place the wrist into extension without ... are easily performed in the surgeons office. ...
... slender design contributes to overall low-profile frame ... The Connecting Clamp allows connection of 3.0 ... Uses 3.0 mm Carbon Fiber Rods. The ... to predrill and provide more stability and ...
The DFS MiniFixator is a lightweight, external device for the treatment of small bone fractures and osteotomies....
Medicine Products: